Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Cerebrospinal fluid bioma… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Cerebrospinal fluid biomarkers for Alzheimer's disease: A view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team

Artikel i vetenskaplig tidskrift
Författare S. P. Arnerić
R. Batrla-Utermann
L. Beckett
T. Bittner
Kaj Blennow
L. Carter
R. Dean
S. Engelborghs
J. Genius
M. F. Gordon
J. Hitchcock
J. Kaplow
J. Luthman
R. Meibach
D. Raunig
K. Romero
M. N. Samtani
M. Savage
L. Shaw
D. Stephenson
R. M. Umek
H. Vanderstichele
B. Willis
S. Yule
Publicerad i Journal of Alzheimer's Disease
Volym 55
Nummer/häfte 1
Sidor 19-35
ISSN 1387-2877
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 19-35
Språk en
Länkar dx.doi.org/10.3233/JAD-160573
Ämnesord Alzheimer's disease, biomarker qualification, cerebrospinal fluid biomarkers, Coalition Against Major Diseases
Ämneskategorier Neurovetenskaper, Fysiologi

Sammanfattning

Alzheimer's disease (AD) drug development is burdened with the current requirement to conduct large, lengthy, and costly trials to overcome uncertainty in patient progression and effect size on treatment outcome measures. There is an urgent need for the discovery, development, and implementation of novel, objectively measured biomarkers for AD that would aid selection of the appropriate subpopulation of patients in clinical trials, and presumably, improve the likelihood of successfully evaluating innovative treatment options. Amyloid deposition and tau in the brain, which are most commonly assessed either in cerebrospinal fluid (CSF) or by molecular imaging, are consistently and widely accepted. Nonetheless, a clear gap still exists in the accurate identification of subjects that truly have the hallmarks of AD. The Coalition Against Major Diseases (CAMD), one of 12 consortia of the Critical Path Institute (C-Path), aims to streamline drug development for AD and related dementias by advancing regulatory approved drug development tools for clinical trials through precompetitive data sharing and adoption of consensus clinical data standards. This report focuses on the regulatory process for biomarker qualification, briefly comments on how it contrasts with approval or clearance of companion diagnostics, details the qualifications currently available to the field of AD, and highlights the current challenges facing the landscape of CSF biomarkers qualified as hallmarks of AD. Finally, it recommends actions to accelerate regulatory qualification of CSF biomarkers that would, in turn, improve the efficiency of AD therapeutic development. © 2017 - IOS Press and the authors.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?